Literature DB >> 9851579

The effect of methamphetamine on the release of acetylcholine in the rat striatum.

K Taguchi1, J Atobe, M Kato, T Chuma, T Chikuma, T Shigenaga, T Miyatake.   

Abstract

We examined the effect of methamphetamine on the release of acetylcholine in the striatum of freely moving rats, using an in vivo microdialysis method. The basal level of acetylcholine was 3.67+/-0.47 pmol/30 microl per 15 min in the presence of neostigmine (10 microM). Tetrodotoxin (1 microM), a selective blocker of voltage-dependent Na+ channels, markedly inhibited the release of acetylcholine in the striatal perfusates. Apomorphine (1.0 mg/kg, i.p.), a dopamine receptor agonist, also significantly attenuated acetylcholine release. Methamphetamine (0.1 and 0.5 mg/kg, i.p.) did not immediately affect acetylcholine release in the striatum, but a dose of 1.0 mg/kg (i.p.) induced an increase of acetylcholine release in the striatum at 15-60 min. Striatal infusion of methamphetamine (5 and 10 microM) did not influence acetylcholine release. The increase following intraperitoneal administration of methamphetamine was slightly diminished by haloperidol (0.5 mg/kg). After microinjection of the neurotoxin, 6-hydroxydopamine (6 microg/3 microl), in the substantia nigra 7 days before, the increase of acetylcholine induced by the administration of methamphetamine (1.0 mg/kg) was slightly attenuated, whereas the administration of reserpine (2 mg/kg, i.p.) 24 h before, combined with alpha-methyl-p-tyrosine (300 mg/kg, i.p.) 2.5 h before, completely blocked the increase in release of acetylcholine. These findings suggest that methamphetamine exerts an excitatory influence on striatal acetylcholine release in freely moving rats, and that this excitatory effect involves the dopaminergic system and the catecholaminergic system.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9851579     DOI: 10.1016/s0014-2999(98)00653-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  3,4-Methylenedioxymethamphetamine enhances the release of acetylcholine in the prefrontal cortex and dorsal hippocampus of the rat.

Authors:  Sunila G Nair; Gary A Gudelsky
Journal:  Psychopharmacology (Berl)       Date:  2005-12-24       Impact factor: 4.530

2.  The orexin-1 receptor antagonist SB-334867 decreases sympathetic responses to a moderate dose of methamphetamine and stress.

Authors:  Daniel E Rusyniak; Dmitry V Zaretsky; Maria V Zaretskaia; Pamela J Durant; Joseph A DiMicco
Journal:  Physiol Behav       Date:  2012-02-14

3.  Chronic Nicotine Exposure Attenuates Methamphetamine-Induced Dopaminergic Deficits.

Authors:  Paula L Vieira-Brock; Lisa M McFadden; Shannon M Nielsen; Jonathan D Ellis; Elliot T Walters; Kristen A Stout; J Michael McIntosh; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2015-09-21       Impact factor: 4.030

4.  Safety and efficacy of varenicline to reduce positive subjective effects produced by methamphetamine in methamphetamine-dependent volunteers.

Authors:  Christopher D Verrico; James J Mahoney; Daisy G Y Thompson-Lake; Ryan S Bennett; Thomas F Newton; Richard De La Garza
Journal:  Int J Neuropsychopharmacol       Date:  2014-02       Impact factor: 5.176

5.  Regulation of glutamate release by α7 nicotinic receptors: differential role in methamphetamine-induced damage to dopaminergic and serotonergic terminals.

Authors:  Nicole A Northrop; Laura P Smith; Bryan K Yamamoto; David J Eyerman
Journal:  J Pharmacol Exp Ther       Date:  2010-12-15       Impact factor: 4.030

6.  Comparison of systemic and local methamphetamine treatment on acetylcholine and dopamine levels in the ventral tegmental area in the mouse.

Authors:  L K Dobbs; G P Mark
Journal:  Neuroscience       Date:  2008-08-03       Impact factor: 3.590

Review 7.  Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons.

Authors:  Gary A Gudelsky; Bryan K Yamamoto
Journal:  Pharmacol Biochem Behav       Date:  2007-10-16       Impact factor: 3.533

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.